QTC-4-MeOBnE Ameliorated Depressive-Like Behavior and Memory Impairment in 3xTg Mice

[1]  D. Praticò,et al.  1-(7-Chloroquinolin-4-yl)-N-(4-Methoxybenzyl)-5-Methyl-1H-1,2, 3-Triazole-4- carboxamide Reduces Aβ Formation and Tau Phosphorylation in Cellular Models of Alzheimer’s Disease , 2022, Neurochemical Research.

[2]  D. Praticò,et al.  Beneficial effects of QTC-4-MeOBnE in an LPS-induced mouse model of depression and cognitive impairments: The role of blood-brain barrier permeability, NF-κB signaling, and microglial activation , 2021, Brain, Behavior, and Immunity.

[3]  D. Praticò,et al.  Effect of QTC-4-MeOBnE Treatment on Memory, Neurodegeneration, and Neurogenesis in a Streptozotocin-Induced Mouse Model of Alzheimer's Disease. , 2020, ACS chemical neuroscience.

[4]  Richard N. Jones,et al.  Depression screening in cognitively normal older adults: Measurement bias according to subjective memory decline, brain amyloid burden, cognitive function, and sex , 2020, Alzheimer's & dementia.

[5]  H. Zetterberg,et al.  Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission , 2020, Alzheimer's Research & Therapy.

[6]  A. Young,et al.  Adult Hippocampal Neurogenesis in Major Depressive Disorder and Alzheimer's Disease. , 2020, Trends in molecular medicine.

[7]  D. Praticò,et al.  QTC-4-MeOBnE rescues scopolamine-induced memory deficits in mice by targeting oxidative stress, neuronal plasticity and apoptosis. , 2020, ACS chemical neuroscience.

[8]  S. Engelborghs,et al.  Depressive Symptoms in the Elderly—An Early Symptom of Dementia? A Systematic Review , 2020, Frontiers in Pharmacology.

[9]  Danielle Goldfarb,et al.  Diagnosing and Treating Depression in Patients with Alzheimer’s Disease , 2019, Neurology and Therapy.

[10]  P. Rosenberg,et al.  Depression Synergy With Amyloid and Increased Risk of Cognitive Decline in Preclinical Alzheimer Disease. , 2019, JAMA network open.

[11]  L. Trabace,et al.  Monoaminergic System Modulation in Depression and Alzheimer’s Disease: A New Standpoint? , 2019, Front. Pharmacol..

[12]  L. Savegnago,et al.  Rational design, cognition and neuropathology evaluation of QTC-4-MeOBnE in a streptozotocin-induced mouse model of sporadic Alzheimer’s disease , 2019, Scientific Reports.

[13]  A. Caccamo,et al.  Temporal and regional progression of Alzheimer’s disease‐like pathology in 3xTg‐AD mice , 2018, Aging cell.

[14]  C. Cotman,et al.  Impaired AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease , 2018, Aging cell.

[15]  M. Tremblay,et al.  Chronic stress as a risk factor for Alzheimer's disease: Roles of microglia-mediated synaptic remodeling, inflammation, and oxidative stress , 2018, Neurobiology of Stress.

[16]  Daniel C Alexander,et al.  Data-driven models of dominantly-inherited Alzheimer’s disease progression , 2018, bioRxiv.

[17]  Keith A. Johnson,et al.  Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. , 2018, The American journal of psychiatry.

[18]  R. Lam,et al.  Cognitive Impairment in Patients With Depression: Awareness, Assessment, and Management. , 2017, The Journal of clinical psychiatry.

[19]  Ying Yang,et al.  Melatonin ameliorates anxiety and depression‐like behaviors and modulates proteomic changes in triple transgenic mice of Alzheimer's disease , 2017, BioFactors.

[20]  D. Steffens.  Late-Life Depression and the Prodromes of Dementia. , 2017, JAMA psychiatry.

[21]  N. Kato,et al.  Impaired retention of depression-like behavior in a mouse model of Alzheimer's disease , 2017, IBRO reports.

[22]  G. Hankey,et al.  Depression as a modifiable factor to decrease the risk of dementia , 2017, Translational Psychiatry.

[23]  T. Yen,et al.  Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study , 2017, EJNMMI Research.

[24]  D. Praticò,et al.  12/15-Lipoxygenase Inhibition Reverses Cognitive Impairment, Brain Amyloidosis, and Tau Pathology by Stimulating Autophagy in Aged Triple Transgenic Mice , 2017, Biological Psychiatry.

[25]  L. Tan,et al.  The Role of ADAM10 in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[26]  Keith A. Johnson,et al.  Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. , 2017, Journal of Alzheimer's disease : JAD.

[27]  A. Fagan,et al.  Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. , 2016, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[28]  Xin Jin,et al.  Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer’s disease model , 2016, Scientific Reports.

[29]  N. Greig,et al.  Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. , 2015, Current Alzheimer research.

[30]  R. Jope,et al.  Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. , 2015, Pharmacology & therapeutics.

[31]  S. Graham,et al.  Brain derived neurotrophic factor is involved in the regulation of glycogen synthase kinase 3β (GSK3β) signalling. , 2014, Biochemical and biophysical research communications.

[32]  E. Chen,et al.  N-Cadherin Promotes Recruitment and Migration of Neural Progenitor Cells from the SVZ Neural Stem Cell Niche into Demyelinated Lesions , 2014, The Journal of Neuroscience.

[33]  R. Petersen,et al.  Parallels Between Major Depressive Disorder and Alzheimer’s Disease: Role of Oxidative Stress and Genetic Vulnerability , 2014, Cellular and Molecular Neurobiology.

[34]  Sunyoung Kim,et al.  GSK3β, but not GSK3α, inhibits the neuronal differentiation of neural progenitor cells as a downstream target of mammalian target of rapamycin complex1. , 2014, Stem cells and development.

[35]  R. Tanzi,et al.  ADAM10 Missense Mutations Potentiate β-Amyloid Accumulation by Impairing Prodomain Chaperone Function , 2013, Neuron.

[36]  T. Goldberg,et al.  Elevated CSF Tau is associated with psychosis in Alzheimer's disease. , 2013, The American journal of psychiatry.

[37]  J. García-Verdugo,et al.  Dual effects of increased glycogen synthase kinase-3β activity on adult neurogenesis. , 2013, Human molecular genetics.

[38]  D. Foguel,et al.  Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice , 2012, Molecular Psychiatry.

[39]  K. S. Al-Harbi.  Treatment-resistant depression: therapeutic trends, challenges, and future directions , 2012, Patient preference and adherence.

[40]  F. LaFerla,et al.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. , 2012, Current pharmaceutical design.

[41]  B. Winblad,et al.  Depression in dementia: epidemiology, mechanisms, and treatment , 2011, Current opinion in psychiatry.

[42]  R. Dyck,et al.  Characterization of the 3xTg-AD mouse model of Alzheimer's disease: Part 2. Behavioral and cognitive changes , 2010, Brain Research.

[43]  E. Mufson,et al.  Staging of Alzheimer's Pathology in Triple Transgenic Mice: A Light and Electron Microscopic Analysis , 2010, International journal of Alzheimer's disease.

[44]  T. Südhof,et al.  Neuroligin-1 Deletion Results in Impaired Spatial Memory and Increased Repetitive Behavior , 2010, The Journal of Neuroscience.

[45]  F. Fahrenholz,et al.  ADAM-10 over-expression increases cortical synaptogenesis , 2008, Neurobiology of Aging.

[46]  B. Leonard.  Inflammation, Depression and Dementia: Are they Connected? , 2007, Neurochemical Research.

[47]  J. Lieberman,et al.  Metalloprotease-induced ectodomain shedding of neural cell adhesion molecule (NCAM). , 2006, Journal of neurobiology.

[48]  David Loewenstein,et al.  Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. , 2006, Archives of general psychiatry.

[49]  Michael A Rapp,et al.  Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. , 2006, Archives of general psychiatry.

[50]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[51]  R. Green,et al.  Depression as a risk factor for Alzheimer disease: the MIRAGE Study. , 2003, Archives of neurology.

[52]  Xiaohua Li,et al.  BDNF‐mediated signal transduction is modulated by GSK3β and mood stabilizing agents , 2002, Journal of neurochemistry.

[53]  R. Porsolt,et al.  Depression: a new animal model sensitive to antidepressant treatments , 1977, Nature.

[54]  K. Spence,et al.  An experimental test of the sign-gestalt theory of trial and error learning. , 1946 .